Table 35 (Abstract P124). See text for description
From: Proceedings of the 24th Paediatric Rheumatology European Society Congress: Part one
ciGEnC treatment | Pro-inflammatory factors | Protein concentration (pg/ml)/surface expression Median/GeoMean Fluoresecence; IQR, n = 6) Untreated Stimulated | |
|---|---|---|---|
TNF-α | · GM-CSF | (0; 0-0) | (197.7; 189.7-272.3, P = 0.049) |
· MIP-1α | (208.5; 207-209) | (222.3; 221-223.3, P = 0.048) | |
· ICAM-1 | (247.5; 211.5-279) | (443; 353.3-472.3, P = 0.009) | |
IL-1β | · IL-6 | (30.55; 16.9-108.5) | (3479; 1815-5243, P = 0.0004) |
· GM-CSF | (0; 0-0) | (950.5; 464.9-1128, P = 0.0004) | |
· TNF-α | (4.484; 3.717-4.383) | (10.60; 7.048-12.71, P = 0.011) | |
· MIP-1α | (208.5; 207-209) | (221.5; 215.8-225.8, P = 0.049) | |
IFN-γ | · IL-10 | (0.514; 0.370-0.610) | (18.19; 15.69-19.77, P = 0.004) |
· TNF-α | (4.484; 3.717-4.383) | (8.381; 7.270-8.825, P = 0.029) | |
· IP-10 | (2.387; 2.279-3.688) | (3015; 2642-3114, P = 0.008) | |
IL-13 | · sVCAM-1 | (191.8; 88.54-559.1) | (1539; 1033-1646, P = 0.022) |
Combined cytokine treatment | · MCP-1 | (800.1; 446-1705) | (3755; 3359-3911, P = 0.008) |
· M-CSF | (192.4; 85.19-1427) | (3461; 2093-5098, P = 0.021) | |
· VCAM-1 | (59.60; 49.65-69.58) | (119; 85.13-163.3, P = 0.005) | |
LPS | · IL-6 | (30.55; 16.9-108.5) | (3323; 2083-4886, P = 0.0007) |
· IL-10 | (0.514; 0.370-0.610) | (17.32; 9.014-20.25, P = 0.009) | |
· GM-CSF | (0; 0-0) | (312.2; 125.5-576.5, P = 0.017) | |
· IFN-γ | (0; 0-0) | (28.47; 12.14-40.44, P = 0.003) | |
· TNF-α | (4.484; 3.717-4.383) | (14.60; 10.38-20.15, P = 0.0005) | |
· IP-10 | (2.387; 2.279-3.688) | (2870; 1042-3147, P = 0.013) | |